19 completed, 4 terminated, 2 withdrawn, 1 active not recruiting. 15 Phase 1, 11 Phase 2, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 15 | Completed 12, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 11 | Completed 6, Terminated 3, Active not recruiting 1, Unknown 1 |
| Phase 3 | 4 | Completed 3, Terminated 1 |
Follow glasdegib: new trials by email Literature Review of glasdegib trials Research Report on glasdegib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation Bosutinib Monohydrate, Decitabine, Enasidenib Mesylate - Recurrent Acute Myeloid Leukemia | Phase 1 | Withdrawn | City of Hope Medical Center | 2022-06-25 | 2022-06-09 | |
| Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML Glasdegib, Azacitidine - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 3 | Completed | Pfizer | 14 | 2021-05-17 | 2023-12-18 |
| Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia) Gemtuzumab Ozogamicin 147, Gemtuzumab Ozogamicin 1, Glasdegib - Acute Myeloid Leukemia | Phase 3 | Terminated | University Hospital Heidelberg | 28 | 2021-04-01 | 2022-07-01 |
| Acute Myeloid Leukemia Real World Treatment Patterns azacitidine, venetoclax, glasdegib - Leukemia, Myeloid, Acute | Withdrawn | Pfizer | 2020-10-31 | 2023-06-07 | ||
| CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia Glasdegib, CPX-351 - Acute Myelogenous Leukemia (AML) Due to Therapy, Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Phase 2 | Active not recruiting | University of California, Irvine | 30 | 2020-02-19 | 2026-07-16 |
| GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia Glasdegib, Decitabine - ACUTE MYELOID LEUKEMIA | Phase 2 | Terminated | Yale University | 1 | 2019-12-06 | 2021-10-15 |
| Glasdegib for Chronic Graft-Versus-Host Disease Glasdegib - Chronic Graft Versus Host Disease, Fasciitis | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 15 | 2019-12-03 | 2024-10-29 |
| Molecular Profiling of Advanced Soft-tissue Sarcomas Nilotinib, Ceritinib, Capmatinib - Soft Tissue Sarcoma | Phase 3 | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 603 | 2019-10-19 | 2026-04-29 |
| A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Glasdegib Glasdegib 100 mg single oral dose - Hepatic Impairment | Phase 1 | Completed | Pfizer | 24 | 2018-11-05 | 2019-05-06 |
| A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia glasdegib, daunorubicin + cytarabine, azacitidine - Leukemia, Myeloid, Acute | Phase 3 | Completed | Pfizer | 730 | 2018-04-20 | 2023-04-21 |
| Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma PF-04449913, Temozolomide Oral Capsule - Glioblastoma | Phase 1 / Phase 2 | Completed | Grupo Español de Investigación en Neurooncología | 75 | 2018-03-15 | 2024-03-28 |
| Glasdegib in Refractory Patients With Sclerotic Chronic Graft-Versus-Host Disease Glasdegib - Sclerodermoid Chronic Graft-Versus-Host Disease (Disorder) | Phase 1 / Phase 2 | Unknown | Grupo Espanol de trasplantes hematopoyeticos y terapia celular | 21 | 2018-01-09 | 2022-03-17 |
| OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia Anti-OX40 Agonist Monoclonal Antibody PF-04518600, Avelumab, Azacitidine - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 50 | 2017-12-27 | 2023-09-05 |
| Glasdegib Absolute Bioavailability Study Glasdegib Oral Tablet, Glasdegib IV infusion - Healthy Volunteer Study | Phase 1 | Completed | Pfizer | 12 | 2017-09-07 | 2017-11-06 |
| Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia Cytarabine, Decitabine, Idarubicin - Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia | Phase 2 | Completed | University of Nebraska | 75 | 2017-07-07 | 2026-03-10 |
| A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH Formulation Glasdegib, High Fat, High Calorie Meal, Rabeprazole - Healthy Volunteers | Phase 1 | Completed | Pfizer | 24 | 2017-05-01 | 2017-08-01 |
| Understanding The Effect Of A Strong CYP3A4 Inducer On Glasdegib Pharmacokinetics Glasdegib, Rifampin - Healthy Volunteers | Phase 1 | Completed | Pfizer | 12 | 2015-05-01 | 2015-06-25 |
| A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients PF-04449913 (Glasdegib), Azacitidine - Myelodysplastic Syndrome, Acute Myeloid Leukemia | Phase 1 | Completed | Pfizer | 73 | 2015-04-28 | 2024-01-19 |
| Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib Glasdegib (PF-04449913), Placebo - Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis | Phase 2 | Terminated | Pfizer | 21 | 2014-10-06 | 2019-01-17 |
| A Study To Understand How Radiolabelled PF-04449913 Is Taken Up By The Body, Broken Down And Then Removed From The Body [14C] PF-04449913 - Healthy | Phase 1 | Completed | Pfizer | 6 | 2014-05-01 | 2014-07-22 |
Showing 20 of 27. Sign in to see all of them.
Leukemia, Myeloid, Acute (13) · Myelodysplastic Syndromes (4) · Leukemia, Myelomonocytic, Chronic (3) · Hematologic Neoplasms (2) · Bronchiolitis Obliterans Syndrome (1) · Fasciitis (1) · Glioblastoma (1) · Graft vs Host Disease (1) · Leukemia (1) · Leukemia, Myeloid (1) · Neoplasm Metastasis (1) · Primary Myelofibrosis (1) · Sarcoma (1)
Pfizer (15) · City of Hope Medical Center (1) · Fred Hutchinson Cancer Center (1) · Grupo Espanol de trasplantes hematopoyeticos y terapia celular (1) · Grupo Español de Investigación en Neurooncología (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · M.D. Anderson Cancer Center (1) · University Hospital Heidelberg (1) · University of California, Irvine (1) · University of Colorado, Denver (1) · University of Nebraska (1) · Yale University (1)
United States (20) · Spain (5) · Canada (4) · France (4) · Germany (4) · Italy (4) · Japan (4) · Poland (3) · United Kingdom (3) · Austria (2) · Belgium (2) · Czechia (2) · Hungary (2) · Mexico (2) · Australia (1)
Amer M Zeidan, MBBS (1) · Antoine Italiano (1) · Daniel A Pollyea, MD, MS (1) · Deepa Jeyakumar, MD (1) · Guido Marcucci (1) · Jeffrey Lancet, M.D. (1) · Naval G Daver (1) · Stephanie Lee (1) · Vijaya R Bhatt, MD (1)
PMID 33993815, PMID 37698881, PMID 25388167, PMID 26688487, PMID 29463550, PMID 29488303, PMID 30074259, PMID 30536154, PMID 30555165, PMID 30977980, PMID 31516032, PMID 32664995, PMID 32713836, PMID 32885274, PMID 33356019, PMID 33740113, PMID 34732236, PMID 34740331, PMID 35442137, PMID 35450817, PMID 35488900, PMID 37604981, PMID 38000343, PMID 40298352
2017 (5), 2014 (2), 2009 (1), P30CA033572 (1), P30CA036727 (1)